Impaired Gait, Postural Instability, and Rigidity in Relation to CB1 Receptor Availability in Parkinson's Disease.
CB1R
ECS
PET
Parkinson's disease
UPDRS
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
22 Oct 2024
22 Oct 2024
Historique:
revised:
11
10
2024
received:
30
04
2024
accepted:
14
10
2024
medline:
22
10
2024
pubmed:
22
10
2024
entrez:
22
10
2024
Statut:
aheadofprint
Résumé
In Parkinson's disease (PD), postural instability and gait disorder (PIGD) symptoms are associated with a worse prognosis for an unknown reason. The objective was to explore the relationship between cannabinoid receptor type 1 (CB1R) availability and motor symptoms in PD with [ Fifteen individuals with PD underwent [ A negative correlation was observed between [ Gait, postural instability, and rigidity in PD are associated with decreased CB1R availability, unlike tremor or bradykinesia, suggesting that the endocannabinoid system has a role in the pathophysiology of different motor symptoms in PD. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
BACKGROUND
In Parkinson's disease (PD), postural instability and gait disorder (PIGD) symptoms are associated with a worse prognosis for an unknown reason.
OBJECTIVE
OBJECTIVE
The objective was to explore the relationship between cannabinoid receptor type 1 (CB1R) availability and motor symptoms in PD with [
METHODS
METHODS
Fifteen individuals with PD underwent [
RESULTS
RESULTS
A negative correlation was observed between [
CONCLUSIONS
CONCLUSIONS
Gait, postural instability, and rigidity in PD are associated with decreased CB1R availability, unlike tremor or bradykinesia, suggesting that the endocannabinoid system has a role in the pathophysiology of different motor symptoms in PD. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Academy of Finland
ID : 310962
Organisme : Sigrid Juséliuksen Säätiö
Organisme : Turun Yliopistosäätiö
Organisme : Turun yliopiston tutkijakoulu
Informations de copyright
© 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Harkany T, Guzmán M, Galve‐Roperh I, Berghuis P, Devi LA, Mackie K. The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci 2007;28(2):83–92. https://doi.org/10.1016/j.tips.2006.12.004
Lu HC, MacKie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry 2016;79(7):516–525. https://doi.org/10.1016/j.biopsych.2015.07.028
Kruk‐Slomka M, Dzik A, Budzynska B, Biala G. Endocannabinoid system: the direct and indirect involvement in the memory and learning processes—a short review. Mol Neurobiol 2017;54(10):8332–8347. https://doi.org/10.1007/s12035-016-0313-5
Bisogno T, Berrendero F, Ambrosino G, et al. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun 1999;256:377–380. https://doi.org/10.1006/bbrc.1999.0254
Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990;87:1932–1936. https://doi.org/10.1073/pnas.87.5.1932
Jankovic J, McDermott M, Carter J, et al. Variable expression of parkinson's disease: a base‐line analysis of the datatop cohort. Neurology 1990;40(10):1529–1534. https://doi.org/10.1212/wnl.40.10.1529
Aleksovski D, Miljkovic D, Bravi D, Antonini A. Disease progression in Parkinson subtypes: the PPMI dataset. Neurol Sci 2018;39(11):1971–1976. https://doi.org/10.1007/s10072-018-3522-z
Poletti M, Frosini D, Pagni C, et al. Mild cognitive impairment and cognitive‐motor relationships in newly diagnosed drug‐naive patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;83(6):601–606. https://doi.org/10.1136/jnnp-2011-301874
Van Der Heeden JF, Marinus J, Martinez‐Martin P, Rodriguez‐Blazquez C, Geraedts VJ, Van Hilten JJ. Postural instability and gait are associated with severity and prognosis of Parkinson disease. Neurology 2016;86(24):2243–2250. https://doi.org/10.1212/WNL.0000000000002768
Choi SM, Kim BC, Cho BH, et al. Comparison of two motor subtype classifications in de novo Parkinson's disease. Park Relat Disord 2018;54:74–78. https://doi.org/10.1016/j.parkreldis.2018.04.021
Ajalin RM, Al‐Abdulrasul H, Tuisku JM, et al. Cannabinoid receptor type 1 in Parkinson's disease: a positron emission tomography study with [18F]FMPEP‐d2. Mov Disord 2022;37(8):1673–1682. https://doi.org/10.1002/mds.29117
Walker IM, Cousins KA, Siderowf A, et al. Non‐tremor motor dysfunction in Lewy body dementias is associated with AD biomarkers. Park Relat Disord 2022;100:33–36. https://doi.org/10.1016/j.parkreldis.2022.05.022
Lahdenpohja S, Keller T, Forsback S, et al. Automated GMP production and long‐term experience in radiosynthesis of CB1 tracer [18F]FMPEP‐d2. J Label Compd Radiopharm 2020;63(9):408–418. https://doi.org/10.1002/jlcr.3845
Rorden C, Bonilha L, Fridriksson J, Bender B, Karnath HO. Age‐specific CT and MRI templates for spatial normalization. Neuroimage 2012;61(4):957–965. https://doi.org/10.1016/j.neuroimage.2012.03.020
Williams‐Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson's disease: 10‐year outlook in an incident population‐based cohort. J Neurol Neurosurg Psychiatry 2013;84(11):1258–1264. https://doi.org/10.1136/jnnp-2013-305277
García DS, Canfield H, De Deus FT, et al. Parkinson's disease motor subtypes change with the progression of the disease: results from the COPPADIS cohort at 2‐year follow‐up. J Parkinsons Dis 2022;12(3):935–955. https://doi.org/10.3233/JPD-213004
Pikstra ARA, Van Der Hoorn A, Leenders KL, De Jong BM. Relation of 18‐F‐dopa PET with hypokinesia‐rigidity, tremor and freezing in Parkinson's disease. Neuroimage Clin 2016;11:68–72. https://doi.org/10.1016/j.nicl.2016.01.010
Pavese N, Evans AH, Tai YF, et al. Clinical correlates of levodopa‐induced dopamine release in Parkinson disease: a PET study. Neurology 2006;67(9):1612–1617. https://doi.org/10.1212/01.wnl.0000242888.30755.5d
Pasquini J, Ceravolo R, Qamhawi Z, et al. Progression of tremor in early stages of Parkinson's disease: a clinical and neuroimaging study. Brain 2018;141(3):811–821. https://doi.org/10.1093/brain/awx376
Bohnen NI, Frey KA, Studenski S, et al. Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology 2013;81(18):1611–1616. https://doi.org/10.1212/WNL.0b013e3182a9f558
Kinnerup MB, Sommerauer M, Damholdt MF, et al. Preserved noradrenergic function in Parkinson's disease patients with rest tremor. Neurobiol Dis 2021;152:105295. https://doi.org/10.1016/j.nbd.2021.105295
Van Der Stelt M, Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 2003;480:133–150. https://doi.org/10.1016/j.ejphar.2003.08.101
Warren WG, Papagianni EP, Stevenson CW, Stubbendorff C. In it together? The case for endocannabinoid–noradrenergic interactions in fear extinction. Eur J Neurosci 2022;55(4):952–970. https://doi.org/10.1111/ejn.15200
Glass M, Dragunow M, Faull RLM. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997;77(2):299–318. https://doi.org/10.1016/S0306-4522(96)00428-9
Molina‐Holgado E, Vela JM, Arévalo‐Martín A, et al. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol‐3 kinase/Akt signaling. J Neurosci 2002;22(22):9742–9753. https://doi.org/10.1523/jneurosci.22-22-09742.2002
Boonstra JT, Michielse S, Temel Y, Hoogland G, Jahanshahi A. Neuroimaging detectable differences between Parkinson's disease motor subtypes: a systematic review. Mov Disord Clin Pract 2021;8(2):175–192. https://doi.org/10.1002/mdc3.13107
Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 1999;96(10):5780–5785. https://doi.org/10.1073/pnas.96.10.5780
Dubreucq S, Koehl M, Abrous DN, Marsicano G, Chaouloff F. CB1 receptor deficiency decreases wheel‐running activity: consequences on emotional behaviours and hippocampal neurogenesis. Exp Neurol 2010;224(1):106–113. https://doi.org/10.1016/j.expneurol.2010.01.017
Stelt M, Fox SH, Hill M, et al. A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's disease. FASEB J 2005;19(9):1140–1142. https://doi.org/10.1096/fj.04-3010fje